Morphological and immunohistochemical characteristics of changes in the bronchopulmonary lymph nodes in patients with a new COVID-19 coronavirus infection (based on autopsy results)

Cover Page


Cite item

Full Text

Abstract

Background: Research into the pathogenesis and morphogenesis of new coronavirus infection (COVID-19) is currently a hot topic that requires the accumulation, management and analysis of the data. Understanding the mechanisms of the disease and their characteristics would help to improve diagnostic quality, treatment efficacy and reduce mortality.

Aim: To identify morphological and immunohistochemical characteristics of the bronchopulmonary lymph node tissues in autopsied patients with COVID-19.

Materials and methods: The study was carried out on 44 autopsy samples from patients who were hospitalized and died from the new coronavirus infection COVID-19 in the Moscow Regional Research and Clinical Institute. Macroscopic, histological, and immunohistochemical assessment methods were used.

Results: We found stereotypical abnormalities in the morphology and cellular composition of the lymphoid tissue depending on the duration of the disease. These included signs of B-cell-mediated immunity suppression manifested by a decrease in the number and size of lymphoid follicles and occurs at latest after 7 days from the onset of the disease. In the patients with the disease duration of up to 14 days, the T-cell pool of the lymph nodes is represented mainly by CD4+ T-lymphocytes. With longer duration of the disease, there is a gradual increase in the number of lymphoid follicles and their sizes, with changes of the CD4+ to CD8+ T-cell ratio towards higher CD8+ counts. After 21 days of the disease, the CD4+ to CD8+ ratio levels off.

Conclusion: The results obtained indicate a direct damaging effect of SARS-CoV-2 on the lymph node tissues of the bronchopulmonary group. The possibility of secondary transient immune deficiency and infectious  complications in patients with a new coronavirus infection is discussed.

About the authors

D. N. Fedorov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: mmapath_dnf@mail.ru
ORCID iD: 0000-0001-6697-122X

Dmitry N. Fedorov - MD, PhD, Associate Professor, Head of Department of Pathology.

61/2-13 Shchepkina ul., Moscow, 129110, Tel.: +7 (903) 662 09 10

 

Россия

P. A. Korosteleva

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0001-7867-5241

Polina A. Korosteleva - Pathologist, Department of Pathology.

61/2 Shchepkina ul., Moscow, 129110

Россия

D. I. Zybin

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0001-7087-5441

Dmitry I. Zybin - MD, PhD, Head of Department of Cardiovascular Surgery.

61/2 Shchepkina ul., Moscow, 129110

Россия

M. A. Popov

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0002-0316-8410

Mikhail A. Popov - Cardiovascular Surgeon, Research Fellow, Department of Cardiovascular Surgery.

61/2 Shchepkina ul., Moscow, 129110

 

Россия

V. M. Tyurina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0002-1426-0917

Vlada M. Tyurina - Clinical Resident, Department of Pathology.

61/2 Shchepkina ul., Moscow, 129110

 

Россия

A. V. Varlamov

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru
ORCID iD: 0000-0002-9866-9567

Andrey V. Varlamov - Pathologist, Department of Pathology.

61/2 Shchepkina ul., Moscow, 129110




Россия

References

  1. Министерство здравоохранения Российской Федерации. Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) [Интернет]. Версия 7 (03.06.2020). М.; 2020. 166 с. Доступно на: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/origi-nal/03062020_%D0%9CR_C0VID-19_v7.pdf.
  2. Park WB, Kwon NJ, Choi SJ, Kang CK, Choe PG, Kim JY, Yun J, Lee GW, Seong MW, Kim NJ, Seo JS, Oh MD. Virus Isolation from the First Patient with SARS-CoV-2 in Korea. J Korean Med Sci. 2020;35(7):e84. doi: 10.3346/jkms.2020.35.e84.
  3. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Dro-sten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181 (2):271 -80.e8. doi: 10.1016/j.cell.2020.02.052.
  4. Wang K, Chen W, Zhou YS, Lian JQ, Zhang Z, Du P, Gong L, Zhang Y, Cui HY, Geng JJ, Wang B, Sun XX, Wang CF, Yang X, Lin P, Deng YQ, Wei D, Yang XM, Zhu YM, Zhang K, Zheng ZH, Miao JL, Guo T, Shi Y, Zhang J, Fu L, Wang QY, Bian H, Zhu P, Chen ZN. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein [Internet]. bioRxiv. 2020 Mar 14. doi: 10.1101/2020.03.14.988345.
  5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92.e6. doi: 10.1016/j.cell.2020.02.058.
  6. Perrella A, Trama U, Bernardi FF, Russo G, Monastra L, Fragranza F, Orlando V, Coscioni E. Editorial - COVID-19, more than a viral pneumonia. Eur Rev Med Pharmacol Sci. 2020;24(9):5183-5. doi: 10.26355/eur-rev_202005_21216.
  7. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection - a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727-32. doi: 10.1080/22221751.2020.1746199.
  8. Mason WH. Measles (Chapter 246). In: Klieg-man RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Elsevier; 2016. p. 1542-8.e1.
  9. Gershon AA. Measles Virus (Chapter 160). In: Mandell G, Bennett J, Dolin R. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone; 2009. p. 2229-36.e2.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Fedorov D.N., Korosteleva P.A., Zybin D.I., Popov M.A., Tyurina V.M., Varlamov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies